In mice with tumors, dendritic cells show increased activity of the creatine transporter gene compared to dendritic cells in healthy tissue, reflecting a change in energy metabolism due to the tumor environment.
See the scientific wording
Dendritic cells within tumors in mice exhibit significantly higher expression of the creatine transporter gene compared to dendritic cells in healthy tissue, indicating a metabolic adaptation to energy stress in the tumor microenvironment.
Correlational — new studies may shift this
ObservationalOne low-scoring study links this claim to the outcome, but causation is not established.
What the research says
1 study reviewedSupporting (1)
Cohort StudyHuman
Dendritic cells in tumors need more energy to fight cancer, and they use creatine like a fuel. The study shows that giving creatine helps these cells work better, which means they’re probably pulling in more creatine than normal—just like the claim says.
Contradicting (0)
No contradicting studies found yet
That doesn't mean it's settled — it just means no study has tested the opposite.
Quality-weighted scoring: we follow the GRADE framework — each study is rated High, Moderate, Low, or Very Low based on study design, methodology rigor, and risk of bias. A single high-quality RCT can outweigh several weaker observational studies.
Scores reflect study quality, not just count.
Dendritic cells inside tumors take in more creatine because they need more energy to stay active. They use creatine to quickly make ATP, the energy currency of cells, which lets them signal to other immune cells and attack cancer. Without enough creatine, these dendritic cells cannot function properly and fail to activate the immune response.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting study
How Fit Body Science checks a claim
- 1
We isolate the claim
Health advice from videos, articles and studies is broken down into single, testable claims.
- 2
We find the research
Each claim is matched against peer-reviewed studies, with every source cited by DOI.
- 3
We grade the evidence
Studies are scored on methodology, statistical rigor, transparency and publication quality.
The fitness and health internet is full of confident claims. We check them against real research.
Every claim on this site is traced back to peer-reviewed studies, scored on methodology and reporting quality, and given a verdict you can audit yourself — sources, DOIs and all.
- Full evidence breakdown and mechanism chains
- Ask our AI anything about a claim or its studies
- Get notified when new research changes a verdict
In mice with tumors, dendritic cells show increased activity of the creatine transporter gene compared to dendritic cells in healthy tissue, reflecting a change in energy metabolism due to the tumor environment.
Mechanism
1 studyDendritic cells in tumors bring in more creatine to make more energy, which lets them wake up the immune system to fight cancer. Without this extra creatine, the dendritic cells run out of energy and cannot activate the immune response.
Dendritic cells inside tumors take in more creatine because they need more energy to stay active. They use creatine to quickly make ATP, the energy currency of cells, which lets them signal to other immune cells and attack cancer. Without enough creatine, these dendritic cells cannot function properly and fail to activate the immune response.
Dendritic cells within tumors increase expression of the creatine transporter SLC6A8 to enhance creatine uptake from the microenvironment
Creatine is phosphorylated to phosphocreatine, which serves as a high-energy phosphate reservoir to rapidly regenerate ATP during periods of high energy demand
Elevated ATP levels sustain energy-intensive processes including antigen processing, expression of co-stimulatory molecules, and secretion of inflammatory cytokines
Enhanced dendritic cell activation enables efficient priming of cytotoxic T cells through improved antigen presentation and co-stimulatory signaling
Activated T cells proliferate and release effector molecules such as interferon-gamma and tumor necrosis factor-alpha to target and destroy tumor cells
Evidence from Studies
Supporting (1)
Community contributions welcome
Unknown Title
Dendritic cells in tumors need more energy to fight cancer, and they use creatine like a fuel. The study shows that giving creatine helps these cells work better, which means they’re probably pulling in more creatine than normal—just like the claim says.
Contradicting (0)
Community contributions welcome
Score Breakdown
No multi-axis breakdown available yet. The overall Pro / Against score above is the best signal.
Clinical support requires direct evidence. Mechanistic proxy and tangential studies contribute only to the mechanistic score.
- All linked studies are tangential or mechanistic proxies — no direct test of the claim has been found.
- No clinical evidence is available; the score reflects mechanistic plausibility only.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Systematic Review of Creatine Transporter Gene Expression in Tumor-Associated Dendritic Cells Across Mouse Cancer Models
Population: Mouse models of various cancers; Intervention: None (observational); Comparator: Dendritic cells from tumor tissue vs. healthy tissue; Outcome: Creatine transporter gene expression levels; Duration: All available studies included.
Randomized Control of Creatine Transporter Expression in Tumor-Associated Dendritic Cells in Mice
Population: Mice with implanted tumors; Intervention: Genetic knockdown or overexpression of creatine transporter in dendritic cells; Comparator: Control dendritic cells with normal expression; Outcome: Tumor growth, intracellular creatine levels, energy stress markers; Duration: 4–8 weeks.
Longitudinal Cohort of Creatine Transporter Expression in Dendritic Cells During Tumor Progression in Mice
Population: Mice monitored from tumor initiation to endpoint; Intervention: None; Comparator: Dendritic cells sampled at multiple time points; Outcome: Creatine transporter gene expression and tumor microenvironment energy markers; Duration: Serial sampling over 6–12 weeks.
In Vitro Analysis of Creatine Transporter Expression in Mouse Dendritic Cells Under Energy Stress Conditions
Population: Isolated mouse dendritic cells; Intervention: Exposure to low glucose, hypoxia, or ATP-depleting agents; Comparator: Normal culture conditions; Outcome: Creatine transporter mRNA and protein levels; Duration: 24–72 hours.
Comparative Gene Expression Profiling of Dendritic Cells from Tumor-Bearing vs. Healthy Mice
Population: Tumor-bearing mice vs. age-matched healthy mice; Intervention: None; Comparator: Dendritic cells from tumor tissue vs. lymphoid organs; Outcome: Creatine transporter gene expression via RNA-seq or qPCR; Duration: Single time point post-tumor establishment.